Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis?

D Stakisaitis1, V Basys, R Benetis

  • 1Vilnius University Medical Faculty, Vilnius, Lithuania. donatasstakisaitis@vvkt.it

Insights

Alpha-1-proteinase inhibitor (alpha-1-PI) levels are higher in coronary atherosclerosis patients, especially with hyperlipidemia. The PI*Z gene variant is more common in patients than in long-survivors, suggesting a role in atherogenesis.

Area of Science:

  • Cardiovascular Research
  • Genetics and Atherosclerosis
  • Proteinase-Antiproteinase System

Background:

  • Alpha-1-proteinase inhibitor (alpha-1-PI) plays a role in protecting arterial walls from proteinase damage and lipid accumulation.
  • Imbalances in the proteinase-antiproteinase system may contribute to arterial wall destruction and atherogenesis.

Purpose of the Study:

  • To investigate the association between alpha-1-PI genetic variants and phenotypes with coronary atherosclerosis.
  • To examine serum alpha-1-PI levels in relation to coronary atherosclerosis, hyperlipidemia, and aging.
  • To evaluate the role of alpha-1-PI in atherogenesis by comparing patients with healthy individuals and long-survivors.

Main Methods:

  • Analysis of alpha-1-PI genetic variants and phenotypes in coronary atherosclerosis patients, healthy individuals, and long-survivors.
  • Quantification of serum alpha-1-PI, apoB, and apoA-1 levels using ELISA.
  • Correlation analysis between serum alpha-1-PI concentration, age, and apolipoprotein ratios (apoB/apoA-1).

Main Results:

  • The PI*Z gene was significantly more frequent in coronary atherosclerosis patients than in long-survivors (P<0.01).
  • Serum alpha-1-PI concentration was significantly higher in patients with coronary atherosclerosis compared to controls (P<0.05).
  • Alpha-1-PI concentration correlated positively with the apoB/apoA-1 ratio, indicating a link with hyperlipidemia (r=0.25, P<0.05).

Conclusions:

  • Derangements in the proteinase-antiproteinase system, particularly involving alpha-1-PI, may contribute to atherosclerosis.
  • Hyperlipidemia might be associated with systemic inactivation of alpha-1-PI in the atherosclerotic process.
  • Long-survivors serve as a valuable control group for understanding genetic determinants in atherogenesis.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...